LNK01003 / Lynk Pharmaceuticals - LARVOL DELTA

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects (PRNewswire) - "Lynk Pharmaceuticals Co., Ltd...announced that it has recently completed phase I trials in healthy subjects in China for its self-developed innovative intestinal-restricted JAK inhibitor LNK01003. The results of the study showed good safety, tolerability, and pharmacokinetic performance....The results showed that LNK01003 was safe and well tolerated in all dose groups, with no SAEs (serious adverse events), and no TEAEs (adverse events occurring after dosing) leading to discontinuation or early withdrawal."

P1 data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis (PRNewswire) - "Lynk Pharmaceuticals Co., Ltd...announced that it has dosed the first patient in a Phase II clinical trial of its innovative drug LNK01003 in Ulcerative Colitis (UC). This Phase II clinical study will evaluate the efficacy and safety of LNK01003 in patients with active ulcerative colitis."

Trial status • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Lynk Pharmaceuticals inks $50M series B for 3 early-stage trials (FierceBiotech) - "Lynk Pharmaceuticals picked up $50 million in series B funds Friday to bankroll three assets through phase 1 and 2 trials. The Hangzhou, China-based biotech has received the green light to run clinical trials for three drugs in the U.S. and China...The biotech also received clinical trial approval in China for its kinase inhibitor aimed at treating inflammatory bowel disease in June."

Financing • Immunology • Inflammatory Bowel Disease

Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003 (PRNewswire) - "Lynk Pharmaceuticals Co., Ltd...announced today that its new Class I innovative drug LNK01003, has been approved by National Medical Products Administration (NMPA) for clinical trials of inflammatory bowel disease (IBD)."

New trial • Inflammatory Bowel Disease